FDA Set to Unban RFK Jr.'s Favorite Peptides
Gizmodo • • business
Key Points:
- The FDA is preparing to lift a compounding ban on over a dozen peptides, reversing restrictions imposed in 2023 due to safety concerns and limited health data.
- Health Secretary Robert F. Kennedy Jr. had promised this reversal, calling the FDA's previous ban a "war on peptides" and claiming many were unfairly restricted due to lack of proven effectiveness rather than safety issues.
- Popular peptides like BPC-157, cathelicidin LL-37, and epitalon are expected to be among those removed from the restricted list, though the full list has not been disclosed.
- Despite the easing of restrictions, experts warn about potential safety risks and emphasize the need for medical supervision when using peptides, citing concerns including possible deaths linked to some compounds.
- Kennedy’s influence within the administration appears to be waning amid political setbacks, but the FDA's impending policy change marks a significant shift in the regulatory landscape for peptide therapies.
